EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

DprE1 Inhibitors: Enduring Aspirations for Future Antituberculosis Drug Discovery

Saloni Yadav, Aastha Soni, Omprakash Tanwar iD, Rajendra Bhadane iD, Gurdyal S Besra, Neha Kawathekar

ChemMedChem · 15.08.2023 · 18 (16)

DOI: 10.1002/cmdc.202300099 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 29.06.2023. Verfasst von Saloni Yadav und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shri Govindram Seksaria Institute of Technology and Science, 23-Park Road, Indore, Madhya Pradesh, India. Hauptthemen laut MEDLINE: Antitubercular Agents, Mycobacterium tuberculosis. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DprE1 is a crucial enzyme involved in the cell wall synthesis of Mycobacterium tuberculosis and a promising target for antituberculosis drug development. However, its unique structural characteristics for ligand binding and association with DprE2 make developing new clinical compounds challenging. This review provides an in‐depth analysis of the structural requirements for both covalent and non‐covalent inhibitors, their 2D and 3D binding patterns, as well as their biological activity data in vitro and in vivo, including pharmacokinetic information. We also introduce a protein quality score (PQS) and an active‐site map of the DprE1 enzyme to help medicinal chemists better understand DprE1 inhibition and develop new and effective anti‐TB drugs. Furthermore, we examine the resistance mechanisms associated with DprE1 inhibitors to understand future developments due to resistance emergence. This comprehensive review offers insight into the DprE1 active site, including protein‐binding maps, PQS, and graphical representations of known inhibitors, making it a valuable resource for medicinal chemists working on future antitubercular compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsMycobacterium tuberculosisProtein BindingCatalytic DomainBacterial Proteins

Stichwörter der Autor:innen

DprE1arabinogalactanbenzothiazinonecovalent inhibitorsnoncovalent inhibitorstuberculosis

Substanzen

Antitubercular AgentsBacterial Proteins

Autor:innen und Institutionen

  • Department of Pharmacy, Shri Govindram Seksaria Institute of Technology and Science, 23-Park Road, Indore, Madhya Pradesh, India.
  • Turku Cellular Microbiology Laboratory (TCML), Åbo Akademi University, 20014, Turku, Finland.
  • Institute of Biomedicine, University of Turku, 20520, Turku, Finland.
  • Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.

ORCID-Profile: Omprakash Tanwar, Rajendra Bhadane

Förderung

  • Medical Research Foundation

Zitieren

APA

Yadav, S., Soni, A., Tanwar, O., Bhadane, R., Besra, G. S., & Kawathekar, N. (2023). DprE1 Inhibitors: Enduring Aspirations for Future Antituberculosis Drug Discovery. ChemMedChem, 18(16). https://doi.org/10.1002/cmdc.202300099

Vancouver

Yadav S, Soni A, Tanwar O, Bhadane R, Besra GS, Kawathekar N. DprE1 Inhibitors: Enduring Aspirations for Future Antituberculosis Drug Discovery. ChemMedChem. 2023;18(16). doi:10.1002/cmdc.202300099

BibTeX
@article{Yadav2023,
  author = {Yadav, Saloni and Soni, Aastha and Tanwar, Omprakash and Bhadane, Rajendra and Besra, Gurdyal S and Kawathekar, Neha},
  title = {DprE1 Inhibitors: Enduring Aspirations for Future Antituberculosis Drug Discovery},
  journal = {ChemMedChem},
  year = {2023},
  volume = {18},
  number = {16},
  doi = {10.1002/cmdc.202300099}
}
Kostenlos starten →